Company news
Amplia Therapeutics Ltd. news in 2023
Amplia Therapeutics Ltd.'s news releases, calls and decks from 2023, newest first.
Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
December 3, 2023
Appendix 4D and Financial Report Half Year ended 30 Sep 23
November 20, 2023
Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
October 29, 2023
Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
October 18, 2023
AACR Ovarian Cancer Conference Presentation
October 8, 2023
ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
July 30, 2023
Annual Report to Shareholders
May 30, 2023
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
May 28, 2023
Grant to collaborate with CSIRO Supplementary Announcement
May 23, 2023
Amplia receives grant to collaborate with CSIRO
May 21, 2023
ACCENT Trial Recruitment Progress
May 9, 2023
Quarterly Activities and Cashflow Reports - March 23 Qtr
April 26, 2023
First Patient Recruited to Cohort 3 of ACCENT Trial
April 18, 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
April 11, 2023
First Patient Recruited to Cohort 2 of Accent Trial
February 1, 2023
Quarterly Activities and Cashflow Reports - December 2022
January 29, 2023
Decks in 2023
- Shareholder Meeting (August 2023)
Shareholder meeting · 14 slides · Aug 24, 2023
- 2nd Next Generation Kinase Inhibitors Summit (February 2023)
Conference · 23 slides · Feb 23, 2023